Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia (DEXAML-03)
Dexamethasone Plus Salvage Chemotherapy Versus Salvage Chemotherapy Alone in Patients With First Relapsed or Refractory Acute Myeloid Leukemia: a Randomized, Controlled, Open-label, Multicenter, Phase III Study
Sponsor: University Hospital, Toulouse
Terminated
Despite a recruitment target that was not met, we managed to achieve more than 50% of inclusions and 33% of deaths, enabling us to carry out an initial analysis of the primary endpoint
A PHASE3 clinical study on Relapsed or Refractory Acute Myeloid Leukemia, this trial is terminated or withdrawn. The trial is conducted by University Hospital, Toulouse and has accumulated 10 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
May 2025 — Present [monthly]
Terminated PHASE3
Status: Recruiting → Terminated
-
Sep 2024 — May 2025 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Oct 2023 — Jul 2024 [monthly]
Recruiting PHASE3
-
Sep 2022 — Oct 2023 [monthly]
Recruiting PHASE3
▶ Show 5 earlier versions
-
Jan 2021 — Sep 2022 [monthly]
Recruiting PHASE3
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Dec 2019 — Aug 2020 [monthly]
Not Yet Recruiting PHASE3
-
May 2019 — Dec 2019 [monthly]
Not Yet Recruiting PHASE3
-
Jan 2019 — May 2019 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- University Hospital, Toulouse
For direct contact, visit the study record on ClinicalTrials.gov .